Michael J Vinikoor1,2,3, Edford Sinkala3,4, Roma Chilengi2, Lloyd B Mulenga3,4, Benjamin H Chi5, Zude Zyambo2, Christopher J Hoffmann6, Michael S Saag1, Mary-Ann Davies7, Matthias Egger8, Gilles Wandeler8,9. 1. Department of Medicine, University of Alabama at Birmingham. 2. Centre for Infectious Disease Research in Zambia. 3. School of Medicine, University of Zambia, and. 4. Department of Medicine, University Teaching Hospital, Lusaka, Zambia. 5. Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill. 6. Department of Medicine, Johns Hopkins University, Baltimore, Maryland. 7. School of Public Health and Family Medicine, University of Cape Town, South Africa. 8. Institute of Social and Preventive Medicine, University of Bern, Switzerland. 9. Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland.
Abstract
BACKGROUND: We investigated changes in hepatic fibrosis, based on transient elastography (TE), among human immunodeficiency virus (HIV)-infected patients with and without hepatitis B virus (HBV) coinfection on antiretroviral therapy (ART) in Zambia. METHODS: Patients' liver stiffness measurements (LSM; kiloPascals [kPa]) at ART initiation were categorized as no or minimal fibrosis (equivalent to Metavir F0-F1), significant fibrosis (F2-F3), and cirrhosis (F4). TE was repeated following 1 year of ART. Stratified by HBV coinfection status (hepatitis B surface antigen positive at baseline), we described LSM change and the proportion with an increase/decrease in fibrosis category. Using multivariable logistic regression, we assessed correlates of significant fibrosis/cirrhosis at 1 year on ART. RESULTS: Among 463 patients analyzed (61 with HBV coinfection), median age was 35 years, 53.7% were women, and median baseline CD4+ count was 240 cells/mm3. Nearly all (97.6%) patients received tenofovir disoproxil fumarate-containing ART, in line with nationally recommended first-line treatment. The median LSM change was -0.70 kPa (95% confidence interval, -3.0 to +1.7) and was similar with and without HBV coinfection. Significant fibrosis/cirrhosis decreased in frequency from 14.0% to 6.7% (P < .001). Increased age, male sex, and HBV coinfection predicted significant fibrosis/cirrhosis at 1 year (all P < .05). CONCLUSION: The percentage of HIV-infected Zambian adults with elevated liver stiffness suggestive of significant fibrosis/cirrhosis decreased following ART initiation-regardless of HBV status. This suggests that HIV infection plays a role in liver inflammation. HBV-coinfected patients were more likely to have significant fibrosis/cirrhosis at 1 year on ART. CLINICAL TRIALS REGISTRATION: NCT02060162.
BACKGROUND: We investigated changes in hepatic fibrosis, based on transient elastography (TE), among human immunodeficiency virus (HIV)-infected patients with and without hepatitis B virus (HBV) coinfection on antiretroviral therapy (ART) in Zambia. METHODS: Patients' liver stiffness measurements (LSM; kiloPascals [kPa]) at ART initiation were categorized as no or minimal fibrosis (equivalent to Metavir F0-F1), significant fibrosis (F2-F3), and cirrhosis (F4). TE was repeated following 1 year of ART. Stratified by HBV coinfection status (hepatitis B surface antigen positive at baseline), we described LSM change and the proportion with an increase/decrease in fibrosis category. Using multivariable logistic regression, we assessed correlates of significant fibrosis/cirrhosis at 1 year on ART. RESULTS: Among 463 patients analyzed (61 with HBV coinfection), median age was 35 years, 53.7% were women, and median baseline CD4+ count was 240 cells/mm3. Nearly all (97.6%) patients received tenofovir disoproxil fumarate-containing ART, in line with nationally recommended first-line treatment. The median LSM change was -0.70 kPa (95% confidence interval, -3.0 to +1.7) and was similar with and without HBV coinfection. Significant fibrosis/cirrhosis decreased in frequency from 14.0% to 6.7% (P < .001). Increased age, male sex, and HBV coinfection predicted significant fibrosis/cirrhosis at 1 year (all P < .05). CONCLUSION: The percentage of HIV-infected Zambian adults with elevated liver stiffness suggestive of significant fibrosis/cirrhosis decreased following ART initiation-regardless of HBV status. This suggests that HIV infection plays a role in liver inflammation. HBV-coinfected patients were more likely to have significant fibrosis/cirrhosis at 1 year on ART. CLINICAL TRIALS REGISTRATION: NCT02060162.
Authors: H Nina Kim; Carla V Rodriguez; Stephen Van Rompaey; Joseph J Eron; Chloe L Thio; Heidi M Crane; Edgar T Overton; Michael S Saag; Jeffrey Martin; Elvin Geng; Michael Mugavero; Benigno Rodriguez; W Christopher Mathews; Stephen Boswell; Richard Moore; Mari M Kitahata Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731
Authors: Ana C Tuyama; Feng Hong; Yedidya Saiman; Chuansheng Wang; Derya Ozkok; Arevik Mosoian; Ping Chen; Benjamin K Chen; Mary E Klotman; Meena B Bansal Journal: Hepatology Date: 2010-08 Impact factor: 17.425
Authors: Patrick Marcellin; Edward Gane; Maria Buti; Nezam Afdhal; William Sievert; Ira M Jacobson; Mary Kay Washington; George Germanidis; John F Flaherty; Raul Aguilar Schall; Jeffrey D Bornstein; Kathryn M Kitrinos; G Mani Subramanian; John G McHutchison; E Jenny Heathcote Journal: Lancet Date: 2012-12-10 Impact factor: 79.321
Authors: Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren Journal: Arch Intern Med Date: 2006 Aug 14-28
Authors: Karsten Wursthorn; Mechthild Jung; Antonio Riva; Zachary D Goodman; Patricia Lopez; Weibin Bao; Michael P Manns; Heiner Wedemeyer; Nikolai V Naoumov Journal: Hepatology Date: 2010-11 Impact factor: 17.425
Authors: Theodora E M S de Vries-Sluijs; Jurriën G P Reijnders; Bettina E Hansen; Hans L Zaaijer; Jan M Prins; Suzan D Pas; Martin Schutten; Andy I M Hoepelman; Clemens Richter; Jan W Mulder; Rob A de Man; Harry L A Janssen; Marchina E van der Ende Journal: Gastroenterology Date: 2010-08-26 Impact factor: 22.682
Authors: Alexander J Stockdale; Richard Odame Phillips; Apostolos Beloukas; Lambert Tetteh Appiah; David Chadwick; Sanjay Bhagani; Laura Bonnett; Fred Stephen Sarfo; Geoffrey Dusheiko; Anna Maria Geretti Journal: Clin Infect Dis Date: 2015-05-28 Impact factor: 9.079
Authors: Kasha P Singh; Megan Crane; Jennifer Audsley; Anchalee Avihingsanon; Joe Sasadeusz; Sharon R Lewin Journal: AIDS Date: 2017-09-24 Impact factor: 4.177
Authors: Marianna K Baum; Javier A Tamargo; Richard L Ehman; Kenneth E Sherman; Jun Chen; Qingyun Liu; Raul N Mandler; Colby Teeman; Sabrina S Martinez; Adriana Campa Journal: Drug Alcohol Depend Date: 2021-01-19 Impact factor: 4.492
Authors: Richard K Sterling; Wendy C King; Mandana Khalili; Raymond T Chung; Mark Sulkowski; Mamta K Jain; Mauricio Lisker-Melman; Marc G Ghany; David K Wong; Amanda S Hinerman; Atul K Bhan; Abdus S Wahed; David E Kleiner Journal: Hepatology Date: 2021-08-25 Impact factor: 17.298